Activist Investor Galloway Capital Takes 8.42% Stake in WW International
WW International rose after Galloway Capital built 8.42% stake, saying company is undervalued despite debt issues.
WW International rose after Galloway Capital built 8.42% stake, saying company is undervalued despite debt issues.
WW International reported Q4 and full-year 2025 results beating guidance, with strong growth in clinical subscribers thanks to GLP-1 integration.
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.